# Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma

> **NCT07725380** · PHASE1,PHASE2 · RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 74 (estimated)

## Conditions studied

- Sarcoma
- Osteosarcoma

## Interventions

- **DRUG:** Domatinostat
- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT07725380
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-15
- **Primary completion:** 2031-08
- **Final completion:** 2031-08
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2026-09-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07725380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07725380, "Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07725380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*